breast-pathology-medchem-2018-posters

Page 77

Journal of Clinical & Experimental Pathology | ISSN: 2161-0681 | Volume 8

Breast Pathology and Cancer Diagnosis

World Congress and Expo on

July 25-26, 2018 | Vancouver, Canada

Medicinal Chemistry and Rational Drugs

International Conference on

Comparision of serum prolactin level in persons with and without endometrial cancer

Sinaei S, Rahmani Z, Hafezan S

and

Vahedi A

Tabriz University of Medical Sciences, Iran

Introduction:

Endometrial carcinoma is the most common gynecological malignancy in the developed countries. The early detection

of this disease can change that to a disease which can mostly be cured. Recently Prolactin has been known as a Hormone,Cytocine

that has an increased level in some malignancies,The aim of this study is Comparision of serum prolactin level in persons with and

without endometrial cancer.

Methods:

In comparative-descriptive study,we studied 50 women in the form of two 25 cases groups(first group, 25 patient with

endometrial cancer,and the second group 25 cases without endometrial cancer) refferring to Tabriz Alzahra and Taleghani hospitals

durin the 2011 after achieving the inclusion criteria. Demographic data was recorded for all patients mserum Prolactin levels was

assessed for all patients using Elisa method. All the information was comapred and analyzed using SPSS software.

Results:

The mean age of subjects with disease was 54.84±6.66 years, and the mean age of healthy subjects was 52.64±5.47 years,the

difference in two groups was not statistically significant(p=0.433). The two groups was matched for marital status and occupational

status(P=1 and P=0.856 respectively).The mean serum prolactin levels in group with endometrail cancer was 525.72±290.86 ng/ml

and in the group without endometrial cancer was 258.16±113.28 ng/ml which was significantly higher in the patients group(p<0.001).

Conclusion:

With regard to the findings of this study we can conclude that serum prolactin levels in patients with endometrial cancer

is significantly higher that the level of this hormone in healthy subjects,we can use this hormone measurment for forecasting the

incidence of this disease in high risk popualtion, identification of the specificity and sensitivity of this marker is recommended using

multicenter studies.

J Clin Exp Pathol 2018, Volume 8

DOI: 10.4172/2161-0681-C3-052